Related Experiment Video

Updated: Aug 13, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma

T Nakashima1, G L Clayman

  • 1Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Archives of Otolaryngology--Head & Neck Surgery
|August 2, 2000
PubMed
Abstract

Insights

Overexpression of cyclin D1 drives head and neck cancer growth and cisplatin resistance. Suppressing cyclin D1 may offer a new gene therapy for head and neck squamous cell carcinoma (SCCHN).

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Head and neck squamous cell carcinoma (SCCHN) is a significant global health concern.
  • The role of specific cell cycle regulators like cyclin D1 in SCCHN progression is not fully elucidated.
  • Understanding molecular drivers is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the function of cyclin D1 in regulating the biological behavior of head and neck cancer.
  • To assess the impact of down-regulating cyclin D1 on SCCHN cell proliferation, tumorigenicity, and chemosensitivity.

Main Methods:

  • Stable transfection of SCCHN cell lines with antisense cyclin D1 using lipofectin.
  • In vitro assays including growth, cell cycle, and cytotoxicity analyses.
  • In vivo tumorigenicity studies in athymic nude mice.

Main Results:

  • Antisense cyclin D1 transfection significantly reduced in vitro growth rates and in vivo tumor formation.
  • Down-regulation of cyclin D1 enhanced chemosensitivity to cisplatin.
  • These findings indicate cyclin D1's critical role in SCCHN malignancy.

Conclusions:

  • Overexpression of cyclin D1 is implicated in the accelerated growth and malignant phenotype of human head and neck cancers.
  • Cyclin D1 expression may confer resistance to platinum-based chemotherapy in SCCHN.
  • Targeting cyclin D1 through gene therapy presents a promising strategy for SCCHN treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...